文章：

MoLEP与HoLEP治疗良性前列腺增生：一项基于1368例病例的希腊单中心3年回顾性队列比较研究

MoLEP vs. HoLEP for BPH: A 3-Year Greek Single-Center Retrospective Comparative Cohort Study on 1368 Cases

原文发布日期：10 May 2025

DOI: 10.3390/cancers17101608

类型: Article

开放获取: 是

英文摘要：

Background: Holmium Laser Enucleation of the Prostate (HoLEP) is an established treatment for benign prostatic hyperplasia (BPH). Pulse-modulated lasers, like MOSES technology (MoLEP), may enhance the procedure’s efficiency and safety. Methods: A 3-year single-center retrospective comparative study was conducted on 1368 patients treated with HoLEP/MoLEP at MITERA Hospital. Results: A total of 688 patients were treated with HoLEP and 680 with MoLEP. Compared to HoLEP, MoLEP demonstrated shorter surgical (50.5 min [IQR 33–60] vs. 58 min [IQR 46–69],p< 0.01) and enucleation times (34 min [IQR 23–43] vs. 43 min [IQR 34–51],p< 0.001) and shorter hospital stay (8 h [IQR 6–19] vs. 12 h [IQR 9–24],p= 0.027), catheterization time (19 h [IQR 12–48] vs. 24 h [IQR 24–48],p< 0.001), and irrigation duration (5 h [IQR 2–8] vs. 7 h [IQR 3–10],p< 0.001), with similar morcellated tissue weight and morcellation time. At 1 month, MoLEP showed higher Qmax (27.3 mL/s [IQR 23.9–30.3] vs. 20 mL/s [IQR 17–23.6],p< 0.001), lower PVR (11.4 mL [IQR 7.7–15] vs. 12.5 mL [IQR 7–18],p= 0.005), better IPSS (4 [IQR 3–6] vs. 7 [IQR 5–11],p< 0.005), QoL (1 [IQR 1–2] vs. 2 [IQR 1–2],p< 0.001), lower PSA (1.8 ng/mL [IQR 1.1–2.6] vs. 2.4 ng/mL [IQR 1.3–3.5],p< 0.001), which were maintained at 6 months, and fewer Clavien-Dindo I (2.5% vs. 7.5%,p< 0.001) and II (16% vs. 25.7%,p< 0.001) complications. Conclusions: MoLEP offered significant advantages over HoLEP in this study.

摘要翻译： 

背景：钬激光前列腺剜除术（HoLEP）是治疗良性前列腺增生（BPH）的成熟方法。脉冲调制激光技术，如MOSES技术（MoLEP），可能提升手术效率与安全性。方法：本研究在MITERA医院对1368例接受HoLEP/MoLEP治疗的患者进行了为期3年的单中心回顾性比较研究。结果：共纳入688例HoLEP患者与680例MoLEP患者。与HoLEP相比，MoLEP显示出更短的手术时间（50.5分钟[IQR 33–60] vs. 58分钟[IQR 46–69], p<0.01）和剜除时间（34分钟[IQR 23–43] vs. 43分钟[IQR 34–51], p<0.001），住院时间（8小时[IQR 6–19] vs. 12小时[IQR 9–24], p=0.027）、导尿管留置时间（19小时[IQR 12–48] vs. 24小时[IQR 24–48], p<0.001）及膀胱冲洗时间（5小时[IQR 2–8] vs. 7小时[IQR 3–10], p<0.001）均显著缩短，而组织粉碎重量与粉碎时间两组相似。术后1个月，MoLEP组表现出更高的最大尿流率（27.3 mL/s [IQR 23.9–30.3] vs. 20 mL/s [IQR 17–23.6], p<0.001）、更低的残余尿量（11.4 mL [IQR 7.7–15] vs. 12.5 mL [IQR 7–18], p=0.005）、更佳的国际前列腺症状评分（4分[IQR 3–6] vs. 7分[IQR 5–11], p<0.005）与生活质量评分（1分[IQR 1–2] vs. 2分[IQR 1–2], p<0.001），以及更低的PSA水平（1.8 ng/mL [IQR 1.1–2.6] vs. 2.4 ng/mL [IQR 1.3–3.5], p<0.001），这些优势在术后6个月仍持续存在。此外，MoLEP组的Clavien-Dindo I级（2.5% vs. 7.5%, p<0.001）和II级并发症（16% vs. 25.7%, p<0.001）发生率显著更低。结论：本研究表明，MoLEP相较于HoLEP具有显著优势。

原文链接：

MoLEP vs. HoLEP for BPH: A 3-Year Greek Single-Center Retrospective Comparative Cohort Study on 1368 Cases